SelectQuote（SLQT）株式概要
SelectQuote, Inc.は、米国で保険契約や医療サービスを販売する、テクノロジーを駆使した消費者直販・エンゲージメント・プラットフォームを運営している。 詳細
SLQT Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
SelectQuote, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$1.14 |
| 52週高値 | US$2.80 |
| 52週安値 | US$0.56 |
| ベータ | 1.61 |
| 1ヶ月の変化 | 83.37% |
| 3ヶ月変化 | 3.64% |
| 1年変化 | -58.24% |
| 3年間の変化 | -28.75% |
| 5年間の変化 | -94.70% |
| IPOからの変化 | -95.78% |
最新ニュース
Recent updates
ナラティブ更新 • May 04
SLQT: Reset Assumptions And Profit Margin Focus Will Support Future Upside Potential
SelectQuote’s updated analyst price target has moved to $5.00. Analysts cite adjustments to discount rates, revenue growth assumptions, profit margin expectations, and a revised future P/E of 5.76 as key drivers of the change.
ナラティブ更新 • Apr 20
SLQT: Local Franchise Expansion Will Support Future P/E Re Rating
Analysts have trimmed their price targets on SelectQuote by $1 to $2, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions as the drivers of this shift. Analyst Commentary Bearish analysts cutting price targets by $1 to $2 are signaling that they see less room for upside in SelectQuote at current levels.
ナラティブ更新 • Apr 06
SLQT: Reset Expectations And Pharmacy Agreement Will Support Future Upside
Analysts trimmed their SelectQuote price targets by $1 to $2, citing updated assumptions around discount rates, profit margins and long term P/E expectations that indicate a more cautious outlook on the shares. Analyst Commentary Recent research updates point to a more measured stance on SelectQuote, with price targets trimmed by $1 to $2 as analysts revisit their assumptions around discount rates, profit margins and long term P/E levels.ナラティブ更新 • Mar 22
SLQT: Pharmacy Agreement And Local Expansion Will Support Future P/E Re Rating
Analysts have trimmed their price targets on SelectQuote, with recent Street research indicating cuts of $1 and $2 to reflect revised assumptions around fair value, required return, growth and future P/E expectations. Analyst Commentary Recent Street research highlights a more cautious tone around SelectQuote, with bearish analysts trimming price targets by $1 and $2 to align with their updated assumptions on fair value, required return, growth and future P/E expectations.ナラティブ更新 • Mar 07
SLQT: Reset Expectations And New Pharmacy Agreement Will Support Future Upside
Narrative Update on SelectQuote The consensus analyst price target for SelectQuote has been reduced by a few dollars as analysts reassess their models following recent cuts of $1 and $2 highlighted in new Street research. Analyst Commentary Recent research highlights that the revised price targets reflect updated views on SelectQuote's execution risks and potential for improvement, rather than a complete shift in sentiment.ナラティブ更新 • Feb 21
SLQT: Rebased Expectations And New Pharmacy Agreement Will Support Future Upside
Analysts have trimmed their price targets on SelectQuote, with recent cuts of $1 and $2 contributing to a reduction in our fair value estimate from $4.50 to about $3.06 as they factor in adjusted growth, profitability, and risk assumptions. Analyst Commentary Bullish Takeaways Bullish analysts see the revised price targets as reflecting updated expectations on growth and profitability rather than a fundamental change in the long term opportunity, which they still factor into their models.ナラティブ更新 • Feb 07
SLQT: Reset Assumptions And Pharmacy Agreement Will Support Future Upside Potential
Analysts have lowered their fair value estimate for SelectQuote from US$7.00 to US$5.00. This change reflects updated assumptions around higher discount rates, more modest revenue growth, slimmer profit margins and a higher future P/E multiple.分析記事 • Feb 06
SelectQuote, Inc. (NYSE:SLQT) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the SelectQuote, Inc. ( NYSE:SLQT ) share price has dived 27% in the last thirty...Seeking Alpha • Feb 01
SelectQuote Q2 Earnings Preview: Sell The Medicare Reimbursement News (Rating Downgrade)
Summary SelectQuote is downgraded to sell as Medicare Advantage reimbursement shocks threaten its core business model. SLQT’s fundamentals are deteriorating, with Senior segment profitability slipping and commission revenue at risk from insurer belt-tightening. The 2027 Medicare reimbursement rate increase of just 0.09% is far below expectations, likely pressuring insurer and broker margins. Despite low EBITDA multiples, SLQT’s reliance on insurer commissions and worsening industry outlook justify caution ahead of Q2 earnings. Read the full article on Seeking Alphaナラティブ更新 • Jan 23
SLQT: Future Pharmacy Agreement Will Likely Support P/E Re Rating
Analysts have trimmed their price target on SelectQuote to US$2.00 from US$2.00, citing updated assumptions for discount rate, revenue growth, profit margin and future P/E. Together these factors point to a slightly adjusted risk and earnings profile without changing the headline fair value figure.ナラティブ更新 • Jan 09
SLQT: Future Profitability Shift Will Likely Unlock Deep P/E Re Rating
Analysts have reduced their price target on SelectQuote, citing a lower fair value estimate and higher discount rate, even as updated assumptions point to a higher profit margin and a much lower future P/E multiple of about 2.1x versus 26.2x previously. Valuation Changes The Fair Value Estimate was reduced from 3.0 to 2.0, indicating a lower assessed intrinsic value per share.ナラティブ更新 • Dec 19
SLQT: Expanded Senior Support Services Will Drive Future Upside Potential
Analysts have modestly raised their price target on SelectQuote, citing a slightly higher discount rate and marginally improved long term profitability assumptions. Together, these factors support an incremental increase in estimated equity value of roughly a few cents per share.ナラティブ更新 • Dec 05
SLQT: Expanded Senior Support Partnerships Will Drive Future Upside Potential
Analysts have modestly raised their price target on SelectQuote by refining their discount rate assumptions and reaffirming steady long term revenue growth and profit margin expectations. This has resulted in an updated fair value estimate that is now closer to fundamentals, though it still implies limited upside from current levels.ナラティブ更新 • Nov 21
SLQT: Expanding Senior Referral Program Will Drive Broader Long-Term Support
Analysts have lowered their price target for SelectQuote from $5.00 to $4.50 per share. They cited changes in profit margin forecasts and a higher discount rate as key factors in the revised outlook.分析記事 • Nov 15
Investors Give SelectQuote, Inc. (NYSE:SLQT) Shares A 26% Hiding
The SelectQuote, Inc. ( NYSE:SLQT ) share price has fared very poorly over the last month, falling by a substantial...ナラティブ更新 • Nov 07
SLQT: Expanded Senior Services Will Unlock Long-Term Upside Despite Legal Risks
SelectQuote Price Target Lowered Amid Revised Analyst Outlook Analysts have reduced SelectQuote's price target from $5.25 to $5.00, citing updated forecasts of slower revenue growth and reduced profit margins. What's in the News SelectQuote announced a milestone partnership with Findhelp, which will enable the company to direct over 200,000 low-income seniors to free and discounted social services such as food assistance, housing aid, transportation, healthcare, and financial or legal counseling (Key Developments).分析記事 • Aug 31
SelectQuote, Inc. (NYSE:SLQT) Stock Rockets 30% But Many Are Still Ignoring The Company
SelectQuote, Inc. ( NYSE:SLQT ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...分析記事 • Jul 16
SelectQuote, Inc. (NYSE:SLQT) Could Be Riskier Than It Looks
When close to half the companies operating in the Insurance industry in the United States have price-to-sales ratios...Seeking Alpha • Apr 28
SelectQuote: Better Fundamentals Due To Medicare Advantage Reimbursement Rate Increase (Rating Upgrade)
Summary I'm upgrading SelectQuote to a buy rating after the stock's recent sharp fall. The federal government recently approved a 5.06% reimbursement rate increase for Medicare Advantage plans, which should translate into more aggressive marketing from carriers. This will lead to stronger demand and referral fees for SelectQuote, similar to how the government's premium increase approvals helped EverQuote in the auto insurance industry. SelectQuote is a value stock at <8x forward adjusted EBITDA. Read the full article on Seeking Alpha
新しいナラティブ • Mar 26
Agent Efficiency And Medicare Services Will Transform 2025 Outlook
Improved agent efficiency and optimized marketing reduced expenses, boosting productivity and potentially enhancing margins and earnings.Seeking Alpha • Feb 11
SelectQuote: Better Prospects After Bain Deal, But Don't Rush To Buy (Upgrade)
Summary SelectQuote, Inc. skyrocketed ~30% after posting very strong Q2 results alongside the announcement of a $350 million private infusion from investors led by Bain Capital. Revenue grew 19% year-over-year to $481.1 million, with the Senior division and Health Services arm showing notable improvements in efficiency and subscriber growth. Despite a $350 million investment to reduce debt, SelectQuote remains highly leveraged, and SLQT stock's valuation is not compelling enough to warrant a bullish stance. I'd need to see a turnaround in profitability for the SelectRx division (better than the ~1% adjusted EBITDA margins seen in Q2) to consider buying SLQT stock. Read the full article on Seeking Alpha分析記事 • Jan 18
SelectQuote, Inc. (NYSE:SLQT) Soars 36% But It's A Story Of Risk Vs Reward
Despite an already strong run, SelectQuote, Inc. ( NYSE:SLQT ) shares have been powering on, with a gain of 36% in the...分析記事 • Nov 20
SelectQuote, Inc. (NYSE:SLQT) Stock Rockets 29% But Many Are Still Ignoring The Company
Those holding SelectQuote, Inc. ( NYSE:SLQT ) shares would be relieved that the share price has rebounded 29% in the...分析記事 • Nov 07
SelectQuote, Inc. (NYSE:SLQT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.50
It's been a pretty great week for SelectQuote, Inc. ( NYSE:SLQT ) shareholders, with its shares surging 17% to US$2.34...分析記事 • Oct 03
SelectQuote, Inc. (NYSE:SLQT) Might Not Be As Mispriced As It Looks After Plunging 49%
SelectQuote, Inc. ( NYSE:SLQT ) shares have had a horrible month, losing 49% after a relatively good period beforehand...分析記事 • Jul 02
SelectQuote, Inc. (NYSE:SLQT) Doing What It Can To Lift Shares
When you see that almost half of the companies in the Insurance industry in the United States have price-to-sales...分析記事 • Feb 13
Investors Still Aren't Entirely Convinced By SelectQuote, Inc.'s (NYSE:SLQT) Revenues Despite 29% Price Jump
SelectQuote, Inc. ( NYSE:SLQT ) shares have had a really impressive month, gaining 29% after a shaky period beforehand...Seeking Alpha • Feb 07
SelectQuote Q2: Strong Revenue Growth But Retaining My Hold Rating
Summary SelectQuote, Inc.'s fiscal Q2 revenue of $405.44 million beat estimates, marking the 6th consecutive quarter of increasing YoY revenue. The company raised its revenue guidance for FY 2024 to $1.23 billion to $1.3 billion, a 17% increase from the prior low-end guidance. Despite positive revenue growth, SelectQuote is still losing money and has a significant long-term debt load of $650 million. Read the full article on Seeking AlphaSeeking Alpha • Nov 13
SelectQuote: Insider Buying But A Significant Debt Load
Summary SelectQuote, Inc. is a small-cap online insurance broker with a stock that has had a huge decline since coming public in early 2020. However, the company has made some progress in reducing costs and the shares saw some significant insider purchases in May and September of this year. Time to buy into this improving story? An analysis follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • Nov 08
It's Probably Less Likely That SelectQuote, Inc.'s (NYSE:SLQT) CEO Will See A Huge Pay Rise This Year
Key Insights SelectQuote to hold its Annual General Meeting on 14th of November Total pay for CEO Tim Danker includes...株主還元
| SLQT | US Insurance | US 市場 | |
|---|---|---|---|
| 7D | 23.9% | -1.3% | 2.1% |
| 1Y | -58.2% | -10.0% | 30.6% |
業界別リターン: SLQT過去 1 年間で-10 % の収益を上げたUS Insurance業界を下回りました。
リターン対市場: SLQTは、過去 1 年間で30.6 % のリターンを上げたUS市場を下回りました。
価格変動
| SLQT volatility | |
|---|---|
| SLQT Average Weekly Movement | 18.6% |
| Insurance Industry Average Movement | 4.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: SLQTの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: SLQTの weekly volatility ( 19% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1999 | 4,269 | Tim Danker | www.selectquote.com |
SelectQuote, Inc.は、米国で保険契約や医療サービスを販売する、テクノロジーを駆使した消費者直販・エンゲージメント・プラットフォームを運営している。同社は3つのセグメントで事業を展開している：シニア、ヘルスケアサービス、生命保険。メディケア・アドバンテージ、メディケアサプリメント、メディケアパートD、その他シニア向け医療保険関連商品、リードジェネレーション事業、定期保険、終身保険、その他付帯商品、非商用自動車保険、住宅保険、損害保険商品などを提供している。また、患者中心の薬局であるSelectRx、個人の健康リスクとライフスタイル評価のデータを利用するHealthcare Select、認定薬局であるHomeTM (PCPH)、患者が慢性疾患をナビゲートし、治療計画を用いて管理することを支援するプラットフォームであるSelectPatient Management (SPM)、個人向け自動車保険と住宅保険を提供している。セレクトクオート社は1999年に法人化され、カンザス州オーバーランドパークに本社を置いている。
SelectQuote, Inc. 基礎のまとめ
| SLQT 基礎統計学 | |
|---|---|
| 時価総額 | US$211.62m |
| 収益（TTM） | US$20.76m |
| 売上高(TTM) | US$1.64b |
9.7x
PER（株価収益率0.1x
P/SレシオSLQT は割高か？
公正価値と評価分析を参照収益と収入
| SLQT 損益計算書（TTM） | |
|---|---|
| 収益 | US$1.64b |
| 売上原価 | US$1.07b |
| 売上総利益 | US$576.13m |
| その他の費用 | US$555.37m |
| 収益 | US$20.76m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 0.12 |
| グロス・マージン | 35.09% |
| 純利益率 | 1.26% |
| 有利子負債／自己資本比率 | 56.6% |
SLQT の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/07 21:21 |
| 終値 | 2026/05/07 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/06/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
SelectQuote, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12
| アナリスト | 機関 |
|---|---|
| Steven Valiquette | Barclays |
| Steven Valiquette | Barclays |
| Daniel Grosslight | Citigroup Inc |